Arcturus Therapeutics (ARCT) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Keros Therapeutics (KROS) over the past year, gaining 19.0% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -81.3% for ARCT. Keros Therapeutics is the larger company by market cap ($217.4 million vs $214.7 million), about 1.0 times the size.
Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -80.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | KROS |
|---|---|---|
| Share price | $7.45 | $11.08 |
| Market cap | $214.73M | $217.44M |
| 1-day change | -1.97% | -2.72% |
| YTD return | +21.53% | -45.58% |
| 1-year return | +19.01% | -36.29% |
| 5-year return | -81.32% | -80.25% |
| EPS (TTM) | $-3.10 | $-2.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $243.86M |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $87.01M |
| Operating margin | -92.96% | 27.71% |
| Net margin | -80.19% | 35.68% |
| 52-week high | $17.96 | $22.55 |
| 52-week low | $5.50 | $8.98 |
| Distance from 52-week high | -58.52% | -50.86% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +218.12% | +78.97% |
| Average volume | 851.45K | 196.50K |
| Shares outstanding | 28.82M | 19.62M |
| Employees | 106 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed KROS by 55.3 percentage points over the past year.
- Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -80.2 cents for Arcturus Therapeutics.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ARCT vs KROS FAQ
Which is bigger, Arcturus Therapeutics or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $214.73M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or KROS?
ARCT returned +19.01% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.